{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nBreast cancer remains the most common malignancy among women, underscoring the significant global health burden posed by diverse cancers."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nIn non‐small cell lung cancer (NSCLC), recent studies have elucidated the role of the long non‐coding RNA RAMP2 antisense RNA1 (RAMP2-AS1) as a tumor suppressor. RAMP2-AS1, which is transcribed antisense to the receptor activity-modifying protein 2 (RAMP2) gene, is found to be downregulated in NSCLC tissues along with RAMP2. Functional experiments revealed that overexpression of RAMP2-AS1 inhibits NSCLC cell proliferation and invasion, while promoting apoptosis. Mechanistically, RAMP2-AS1 interacts with the RNA-binding protein T-cell intracellular antigen 1 (TIA1), which in turn stabilizes RAMP2 mRNA, thereby contributing to the suppression of tumor progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nCollectively, these findings highlight a novel regulatory mechanism in NSCLC, suggesting that RAMP2-AS1 may serve as a promising therapeutic target. While the broader landscape of cancer research spans multiple malignancies such as breast cancer, the specific tumor-suppressive action of RAMP2-AS1 in lung cancer emphasizes the critical role of long non-coding RNAs in modulating cancer cell behavior and offers new insights into potential treatment strategies."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Li Li, Ya-Ping Gan, Hui Peng "}, {"type": "b", "children": [{"type": "t", "text": "RAMP2-AS1 inhibits CXCL11 expression to suppress malignant phenotype of breast cancer by recruiting DNMT1 and DNMT3B."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Exp Cell Res (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.yexcr.2022.113139"}], "href": "https://doi.org/10.1016/j.yexcr.2022.113139"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35390315"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35390315"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Siqin Wang, Ce Xu, Yuanyuan Shan, et al. "}, {"type": "b", "children": [{"type": "t", "text": "RAMP2-AS1 stabilized RAPM2 mRNA through TIA1 to inhibit the progression of non-small cell lung cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Mol Biol (Noisy-le-grand) (2023)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.14715/cmb/2023.69.14.2"}], "href": "https://doi.org/10.14715/cmb/2023.69.14.2"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "38279501"}], "href": "https://pubmed.ncbi.nlm.nih.gov/38279501"}]}]}]}